In:
Immunotherapy, Future Medicine Ltd, Vol. 9, No. 3 ( 2017-03), p. 249-259
Abstract:
Aim: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. Patients & methods: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS ® plus, with initial depletion of CD1c + B cells followed by positive selection of CD1c + PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. Results: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. Conclusion: This method was feasible and safe but was minimally immunogenic.
Type of Medium:
Online Resource
ISSN:
1750-743X
,
1750-7448
DOI:
10.2217/imt-2016-0132
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2017